Results
Title

Weekly paclitaxel with pazopanib for heavily treated ovarian cancer.

Authors

Min Chul Choi; Jung-Yun Lee; Jeong-Won Lee

Abstract

Objective: This study investigated the antitumor activity and safety of weekly paclitaxel with pazopanib to for heavily treated ovarian cancer in real-world practice. Methods: We conducted a retrospective study of patients with recurrent epithelial ovarian/fallopian tubal/peritoneal cancer treated with weekly paclitaxel with pazopanib at three tertiary institutions in Korea between September 2018 and August 2023. Patients were received paclitaxel 80 mg/m² intravenously on days 1, 8, and 15 every 28 days with pazopanib 800 mg orally daily. The primary endpoints were response rate, progression-free survival (PFS) rate, overall survival (OS) rate and safety. Results: Data were evaluable for 62 patients. During the median follow-up of 6.6 months (range, 0.2-40.7), response rate was 40.3% (25/62). Median PFS was 5.7 months and median OS was 18.8 months. There were 43.5% (27/62) of grade 3/4 adverse events and toxicity-related discontinuations (17.7%). Severe adverse events were gastrointestinal fistula or perforation (7 events) and liver toxicity (5 events), resulting three treatment-related deaths. Conclusion: The weekly paclitaxel with pazopanib could show the favorable response and increased toxicity to the heavily treated ovarian cancer patients.

Subjects

OVARIAN cancer; PACLITAXEL; PERITONEAL cancer; HEPATOTOXICOLOGY; ANTINEOPLASTIC agents

Publication

Journal of Gynecologic Oncology, 2024, Vol 35, p36

ISSN

2005-0380

Publication type

Academic Journal

DOI

10.3802/jgo.2024.35.S2.P30